115 related articles for article (PubMed ID: 2687858)
21. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
22. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
23. Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.
Birgersson C; Morgan ET; Jörnvall H; von Bahr C
Biochem Pharmacol; 1986 Sep; 35(18):3165-6. PubMed ID: 3753522
[No Abstract] [Full Text] [Related]
24. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Lennard MS; Silas JH; Freestone S; Trevethick J
Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
[TBL] [Abstract][Full Text] [Related]
25. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
26. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
[TBL] [Abstract][Full Text] [Related]
27. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
Bertilsson L; Mellström B; Sjökvist F; Mårtenson B; Asberg M
Lancet; 1981 Mar; 1(8219):560-1. PubMed ID: 6111662
[No Abstract] [Full Text] [Related]
28. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
[TBL] [Abstract][Full Text] [Related]
29. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.
Lou YC; Ying L; Bertilsson L; Sjöqvist F
Lancet; 1987 Oct; 2(8563):852-3. PubMed ID: 2889047
[No Abstract] [Full Text] [Related]
30. Debrisoquine hydroxylation phenotypes in healthy volunteers.
Llerena A; Cobaleda J; Benítez J
Lancet; 1989 Jun; 1(8651):1398. PubMed ID: 2567421
[No Abstract] [Full Text] [Related]
31. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
[TBL] [Abstract][Full Text] [Related]
32. Debrisoquine hydroxylation phenotyping: do we expect too much?
Mitchell SC; Haley CS
Lancet; 1990 Sep; 336(8716):694. PubMed ID: 1975883
[No Abstract] [Full Text] [Related]
33. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
Steiner E; Bertilsson L; Säwe J; Bertling I; Sjöqvist F
Clin Pharmacol Ther; 1988 Oct; 44(4):431-5. PubMed ID: 3168394
[TBL] [Abstract][Full Text] [Related]
34. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.
Yue QY; Bertilsson L; Dahl-Puustinen ML; Säwe J; Sjöqvist F; Johansson I; Ingelman-Sundberg M
Lancet; 1989 Oct; 2(8667):870. PubMed ID: 2571799
[No Abstract] [Full Text] [Related]
35. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
36. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
Küpfer A; Schmid B; Preisig R; Pfaff G
Lancet; 1984 Sep; 2(8401):517-8. PubMed ID: 6147572
[No Abstract] [Full Text] [Related]
37. Debrisoquine phenotype and genotype in Chinese.
Caporaso N; Pickle L
Lancet; 1989 Dec 23-30; 2(8678-8679):1534-5. PubMed ID: 2574814
[No Abstract] [Full Text] [Related]
38. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
[No Abstract] [Full Text] [Related]
39. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
[No Abstract] [Full Text] [Related]
40. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
